RE-BVS – Piemonte Repository

Sfoglia per AUTORE
BOCHICCHIO MT
Collezione AOU Città della Salute di Torino

Items : 6

Safety Run-In and Part 1 of GIMEMA AML1718: Venetoclax Combined with FLAI as Induction Treatment in Non-Low-Risk AML. in Blood advances / Blood Adv. 2025 Mar 6:bloodadvances.2024014901. doi: 10.1182/bloodadvances.2024014901.

2025
AOU Città della Salute di Torino

Marconi G; Piciocchi A; Audisio E; Papayannidis C; Cerrano M; Minotti C; Paoloni F; Guolo F; Bocchia M; Rondoni M; Lico A; Carrabba MG; Della Porta MG; Frigeni M; Giaccone L; Beltrami G; Cattaneo C; Di Chio MC; Serio B; Crea E; Freilone R; Capria S; Curti A; Minetto P; la Sala E; Nanni J; Zannetti BA; Simonetti G; Bochicchio MT; et alii...

Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting. in Cancer / Cancer. 2025 Apr 1;131(7):e35824. doi: 10.1002/cncr.35824.

2025
AOU San Luigi di Orbassano
AOU Città della Salute di Torino
AOU Novara

Marconi G; Petracci E; Valli I; Volpi R; Zamagni F; Mattei A; Ottaviani E; Bochicchio MT; Bocchia M; Todisco E; Cilloni D; Rigolin GM; Giannini MB; Bernardi M; Romani C; Fracchiolla N; Olivieri A; Albano F; Lunghi M; Cambò B; Candoni A; Scappini B; Chiusolo P; Audisio E; Martelli MP; Martinelli G; Mulè A; Papayannidis C; Azzali I; et alii...

Exploring the role of PARP1 inhibition in enhancing antibody-drug conjugate therapy for acute leukemias: insights from DNA damage response pathway interactions. in Journal of translational medicine / J Transl Med. 2024 Nov 26;22(1):1062. doi: 10.1186/s12967-024-05838-9.

2024
AOU Città della Salute di Torino

Ghelli Luserna di Rorà A; Jandoubi M; Padella A; Ferrari A; Marranci A; Mazzotti C; Olimpico F; Ghetti M; Ledda L; Bochicchio MT; Paganelli M; Zanoni M; Cafaro A; Servili C; Galimberti S; Gottardi M; Rondoni M; Endri M; Onofrillo D; Audisio E; Marconi G; Simonetti G; Martinelli G;

Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients. in Leukemia research / Leuk Res. 2021 Feb;101:106497. doi: 10.1016/j.leukres.2020.106497. Epub 2020 Dec 25.

2021
AOU Città della Salute di Torino

Paolini S; Curti A; Bonifazi F; Testoni N; Baldazzi C; Cristiano G; Raffini M; Fontana MC; Parisi S; Ottaviani E; Bochicchio MT; Sartor C; Abbenante MC; Ragaini S; Olivi M; Talami A; Bertamini L; Nanni J; Martinelli G; De Polo S; Marconi G; Cavo M; Papayannidis C;

MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. in European journal of haematology / Eur J Haematol. 2020 Jul;105(1):47-55. doi: 10.1111/ejh.13406. Epub 2020 Apr 7.

2020
AOU Città della Salute di Torino

Marconi G; Talami A; Abbenante MC; Sartor C; Parisi S; Nanni J; Bertamini L; Ragaini S; Olivi M; de Polo S; Cristiano G; Fontana MC; Bochicchio MT; Ottaviani E; Arpinati M; Sessa M; Baldazzi C; Caso L; Testoni N; Baccarani M; Bonifazi F; Martinelli G; Paolini S; Cavo M; Papayannidis C; Curti A;

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib. in American journal of hematology / Am J Hematol. 2017 Aug;92(8):797-805. doi: 10.1002/ajh.24774. Epub 2017 May 30.

2017
AO Ordine Mauriziano
AOU Città della Salute di Torino

Giovanni M; Cavo M; Bochicchio MT; Soverini S; Bocchia M; Gherlinzoni F; Fava C; Bonifacio M; Sica S; Tiribelli M; Usala E; Annunziata M; Pregno P; Orlandi E; Martino B; Cavazzini F; Rossi G; Rupoli S; Vigneri P; Abruzzese E; Albano F; Iurlo A; Levato L; Breccia M; Gugliotta G; Castagnetti F; Saglio G; Pane F; Baccarani M; et alii...